IDYA darovasertib nears NDA completion toward major U.S. milestones
Darovasertib is nearing NDA completion for metastatic uveal melanoma, with a potential U.S. launch in the first half of next year. PRMT5 and DLL3 pipeline assets are also advancing toward major data readouts and trial initiations.
S. launch in the first half of next year and significant commercial opportunity across HLA subgroups. Key pipeline assets, including PRMT5 and DLL3, are advancing, with major data readouts and trial initiations…